Patients with double primary tumors in the breast and ovary - Clinical characteristics and BRCA1-2 mutations status

被引:20
作者
Fishman, A [1 ]
Dekel, E
Chetrit, A
Lerner-Geva, L
Bar-Am, A
Beck, D
Beller, U
Ben-Baruch, G
Piura, B
Friedman, E
Struewing, JP
Modan, B
机构
[1] Meir Hosp, Sapir Med Ctr, IL-44281 Kefar Sava, Israel
[2] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[3] Ichilov Hosp, IL-64239 Tel Aviv, Israel
[4] Rambam Med Ctr, Haifa, Israel
[5] Shaare Zedek Med Ctr, Jerusalem, Israel
[6] Soroka Med Ctr, IL-84101 Beer Sheva, Israel
[7] NCI, Lab Populat Genet, Bethesda, MD 20892 USA
关键词
double primary malignancy; breast cancer; ovarian cancer; BRCA1-2; mutations;
D O I
10.1006/gyno.2000.5895
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The aim of this study was to define the prevalence, clinical characteristics, and BRCA1-2 mutation carrier status of ovarian cancer (OvC) patients with a previous primary malignancy in the breast (PPMBr). Methods. The study population comprised 1240 consecutive Jewish Israeli women with pathologically confirmed epithelial OvC diagnosed between March 1, 1994, and December 31, 1997. Demographic and clinical data were obtained from medical files and from a detailed questionnaire taken through a nationwide epidemiological case-control study on OvC. Blood samples and tumor tissues were collected for analysis of the three predominant germline BRCA1-2 Jewish founder mutations (185delAG, 5382insC, and 6174delT). Results. Fifty nine (4.7%) patients with OvC had a PPMBr. The median age at diagnosis of OvC was 60 years. The mean interval between the two diagnoses was 104 months (range 0-363 months). In the majority of the patients (n = 53), the diagnosis of breast cancer (BrC) preceded the OvC by more than 1 year. The ovarian tumors were diagnosed in 47% of the cases following investigation of patients' symptoms. In 41%, diagnosis was made as a consequence of check-up exams performed during the routine follow-up of BrC survivors. Patients with PPMBr were more likely to present with FIGO ovarian stage III-IV, compared to women with solitary OvC (73% vs 60.3%, P < 0.05), and less likely to have borderline tumors (3.4% vs 17.9%, P = 0.007). Family history of OvC/BrC was recorded in 26% of this group of patients compared to 10.5% among patients with solitary OvC (P = 0.003). Patients with PPMBr had an exceptionally high prevalence of BRCA1-2 mutations (57%), irrespective of family history. Conclusions. Patients with PPMBr present with more advanced disease and invasive-type epithelial ovarian tumors when compared to cases associated with solitary OvC. The rate of BRCA1-2 mutations in Jewish women with OvC who had PPMBr is at least twice as high as in Jewish women with OvC as the solitary disease. (C) 2000 Academic Press.
引用
收藏
页码:74 / 78
页数:5
相关论文
共 36 条
  • [1] Abeliovich D, 1997, AM J HUM GENET, V60, P505
  • [2] Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history
    Berry, DA
    Parmigiani, G
    Sanchez, J
    Schildkraut, J
    Winer, E
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) : 227 - 238
  • [3] HEREDITARY OVARIAN-CANCER - A CLINICOPATHOLOGICAL STUDY
    BEWTRA, C
    WATSON, P
    CONWAY, T
    READHIPPEE, C
    LYNCH, HT
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1992, 11 (03) : 180 - 187
  • [4] Hereditary ovarian cancer: Molecular genetics and clinical implications
    Boyd, J
    Rubin, SC
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 64 (02) : 196 - 206
  • [5] p53 mutations in BRCA1-associated familial breast cancer
    Crook, T
    Crossland, S
    Crompton, MR
    Osin, P
    Gusterson, BA
    [J]. LANCET, 1997, 350 (9078) : 638 - 639
  • [6] CURTIN JP, 1994, OBSTET GYNECOL, V84, P449
  • [7] Curtis R E, 1985, Natl Cancer Inst Monogr, V68, P113
  • [8] MULTIPLE PRIMARY CANCERS OF THE BREAST, ENDOMETRIUM AND OVARY
    EWERTZ, M
    STORM, HH
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (12): : 1927 - 1932
  • [9] Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer
    FitzGerald, MG
    MacDonald, DJ
    Krainer, M
    Hoover, I
    ONeil, E
    Unsal, H
    SilvaArrieto, S
    Finkelstein, DM
    BeerRomero, P
    Englert, C
    Sgroi, DC
    Smith, BL
    Younger, JW
    Garber, JE
    Duda, RB
    Mayzel, KA
    Isselbacher, KJ
    Friend, SH
    Haber, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (03) : 143 - 149
  • [10] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS
    FORD, D
    EASTON, DF
    BISHOP, DT
    NAROD, SA
    GOLDGAR, DE
    HAITES, N
    MILNER, B
    ALLAN, L
    PONDER, BAJ
    PETO, J
    SMITH, S
    STRATTON, M
    LENOIR, GM
    FEUNTEUN, J
    LYNCH, H
    ARASON, A
    BARKARDOTTIR, R
    EGILSSON, V
    BLACK, DM
    KELSELL, D
    SPURR, N
    DEVILEE, P
    CORNELISSE, CJ
    VARSEN, H
    BIRCH, JM
    SKOLNICK, M
    SANTIBANEZKOREF, MS
    TEARE, D
    STEEL, M
    PORTER, D
    COHEN, BB
    CAROTHERS, A
    SMYTH, E
    WEBER, B
    NEWBOLD, B
    BOEHNKE, M
    COLLINS, FS
    CANNONALBRIGHT, LA
    GOLDGAR, D
    [J]. LANCET, 1994, 343 (8899) : 692 - 695